Technical Analysis for MREO - Mereo BioPharma Group plc
Grade | Last Price | % Change | Price Change |
---|---|---|---|
D | 3.09 | -0.64% | -0.02 |
MREO closed down 0.64 percent on Monday, March 18, 2024, on 42 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
Earnings due: Mar 26
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Up | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Lower Bollinger Band Walk | Weakness | 0.00% | |
Down 3 Days in a Row | Weakness | 0.00% | |
Down 4 Days in a Row | Weakness | 0.00% | |
Down 5 Days in a Row | Weakness | 0.00% | |
Gapped Down | Weakness | 0.00% | |
Lower Bollinger Band Touch | Weakness | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
Lower Bollinger Band Walk | Weakness | -0.64% | |
Below Lower BB | Weakness | -0.64% | |
Down 3 Days in a Row | Weakness | -0.64% |
Alert | Time |
---|---|
Rose Above Previous Day's High | about 12 hours ago |
Gap Down Closed | about 14 hours ago |
Reversed from Down | about 14 hours ago |
60 Minute Opening Range Breakout | about 14 hours ago |
Rose Above Lower Bollinger Band | about 17 hours ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 03/26/2024
Mereo is a biopharmaceutical company focused on the development and commercialization of innovative therapeutics that aim to improve outcomes for patients with rare diseases. Mereo's strategy is to selectively acquire product candidates that have substantial preclinical, clinical and manufacturing data packages. Mereo's four product candidates have previously generated positive clinical data for Mereo's target indications or in related indications. Mereo has commenced randomized Phase 2 clinical trials for all four of the product candidates. In connection with the merger with OncoMed, Mereo added two candidates to its pipeline, Navicixizumab and Etigilimab.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Rare Diseases Drug Discovery Clinical Research Clinical Trial Compugen
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Rare Diseases Drug Discovery Clinical Research Clinical Trial Compugen
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 4.36 |
52 Week Low | 0.688 |
Average Volume | 1,950,756 |
200-Day Moving Average | 2.06 |
50-Day Moving Average | 3.50 |
20-Day Moving Average | 3.57 |
10-Day Moving Average | 3.43 |
Average True Range | 0.24 |
RSI (14) | 33.33 |
ADX | 31.4 |
+DI | 12.25 |
-DI | 23.90 |
Chandelier Exit (Long, 3 ATRs) | 3.35 |
Chandelier Exit (Short, 3 ATRs) | 3.66 |
Upper Bollinger Bands | 4.08 |
Lower Bollinger Band | 3.07 |
Percent B (%b) | 0.02 |
BandWidth | 28.32 |
MACD Line | -0.10 |
MACD Signal Line | 0.00 |
MACD Histogram | -0.0954 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 3.31 | ||||
Resistance 3 (R3) | 3.30 | 3.22 | 3.27 | ||
Resistance 2 (R2) | 3.22 | 3.16 | 3.22 | 3.26 | |
Resistance 1 (R1) | 3.15 | 3.13 | 3.19 | 3.16 | 3.25 |
Pivot Point | 3.07 | 3.07 | 3.09 | 3.08 | 3.07 |
Support 1 (S1) | 3.01 | 3.02 | 3.04 | 3.02 | 2.93 |
Support 2 (S2) | 2.93 | 2.98 | 2.93 | 2.92 | |
Support 3 (S3) | 2.86 | 2.93 | 2.91 | ||
Support 4 (S4) | 2.87 |